New approved drug for the treatment of relapsed or refractory pediatric low-grade glioma——Tovorafenib
10.13699/j.cnki.1001-6821.2025.02.020
- VernacularTitle:治疗复发或难治性儿童低级别胶质瘤的新药——Tovorafenib
- Author:
Ting-ting BIAN
1
;
Du-han BO
;
Xin HE
;
Yan-ni CHEN
Author Information
1. 扬州大学医学院附属扬州妇幼保健院药学部,江苏扬州 225000
- Publication Type:Journal Article
- Keywords:
Tovorafenib;
pediatric low-grade glioma;
RAF inhibitor;
the serine threonine kinae v-RAF murine sarcoma viral oncogene homologue B1 gene fusion
- From:
The Chinese Journal of Clinical Pharmacology
2025;41(2):250-253
- CountryChina
- Language:Chinese
-
Abstract:
Tovorafenib has been approved by the U.S.Food and Drug Administration(FDA)for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma(LGGs)harboring the serine threonine kinae v-RAF murine sarcoma viral oncogene homologue B1(BRAF)fusion or rearrangement,or BRAV600E mutation.Tovorafenib is an oral,greater brain-penetrant,selective,type Ⅱ RAF inhibitor which has potent activity against both oncogenic BRAF fusions and BRAFV600E mutations.Most tumors have been showed some degree of shrinkage.The mechanism of action,pharmacodynamics,pharmacokinetics,clinical study and safety were introduced.
